REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 29/03/2019 >View issuer details

2020.09.18 | 09:05 | Permanent Information Releases / General Company News

puce Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO - HTML (w)

2020.09.18 | 09:05 | Permanent Information Releases / General Company News

puce Congrès de l’ESMO : Présentation de dernière minute des données positives d’un essai pivot de Libtayo® (cemiplimab), en monothérapie, dans le traitement du carcinome basocellulaire au stade avancé Libtayo est le premier médicament expérim - HTML (w)

2020.09.18 | 07:00 | Permanent Information Releases / Appointments

puce Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation - HTML (w)

2020.09.18 | 07:00 | Permanent Information Releases / Appointments

puce Le Dr Jean-Christophe Rufin est nommé Président de la Fondation d’entreprise Sanofi Espoir - HTML (w)

2020.09.14 | 07:00 | Permanent Information Releases / General Company News

puce FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis - HTML (w)

2020.09.14 | 07:00 | Permanent Information Releases / General Company News

puce La FDA accorde la désignation de Breakthrough Therapy à Dupixent® (dupilumab) dans le traitement de l’œsophagite à éosinophiles - HTML (w)

2020.09.11 | 18:00 | Share History / Voting Rights and Number of Shares

puce Sanofi : Information concerning the total number of voting rights and shares - July 2020 - HTML (w)

2020.09.11 | 18:00 | Share History / Voting Rights and Number of Shares

puce Sanofi : Informations relatives au nombre total de droits de vote et d’actions - Juillet 2020 - HTML (w)

2020.09.10 | 07:00 | Permanent Information Releases / Sales and Revenues

puce New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A - HTML (w)

2020.09.10 | 07:00 | Permanent Information Releases / Sales and Revenues

puce Le New England Journal of Medicine publie les résultats finaux positifs d’une étude de phase I/IIa consacrée au BIVV001 dans le traitement de l’hémophilie A sévèr - HTML (w)

2020.09.08 | 07:00 | Permanent Information Releases / General Company News

puce Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma - HTML (w)

2020.09.08 | 07:00 | Permanent Information Releases / General Company News

puce Les données à long terme relatives à Dupixent® (dupilumab) montrent une amélioration soutenue de la fonction respiratoire et une réduction des exacerbations sévères chez les adultes et adolescents souffrant d’asthme modéré à sévèr - HTML (w)

2020.09.03 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate - HTML (w)

2020.09.03 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi et GSK lancent un essai clinique de phase I/II de leur candidat-vaccin adjuvanté à base de protéine recombinante contre la COVID-19 - HTML (w)

2020.09.01 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2946